Latest Breaking News On - Halozyme therapeutics company profile - Page 2 : comparemela.com

Halozyme Therapeutics (HALO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $50.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the stock. TD Cowen began coverage on shares of […]

United statesMichaelj labarreHalozyme therapeutics company profileWafra incHsbc holdingsInternational assets investment managementHalozyme therapeutics incHarvey capital management incHalozyme therapeuticsFree reportModerate buyTherapeutics stock downAssets investment managementCapital managementGet free reportHalozyme therapeutics daily

Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelj labarreHalozyme therapeutics company profileSecurities exchange commissionHalozyme therapeutics incHalozyme therapeuticsGet free reportModerate buyExchange commissionHalozyme therapeutics daily

Halozyme Therapeutics (NASDAQ:HALO) Trading Up 5 9%

Halozyme Therapeutics (NASDAQ:HALO) Trading Up 5 9%
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelj labarreRise advisorsHalozyme therapeutics company profileSecurities exchange commissionGoldman sachs groupFidelis capital partnersHalozyme therapeutics incPrincipal securities incWhittier trust coFirst horizon advisors incHalozyme therapeuticsGet free reportExchange commissionCapital partnersFirst horizon advisors

Halozyme Therapeutics (NASDAQ:HALO) Issues FY24 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) Issues FY24 Earnings Guidance
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelj labarreHalozyme therapeutics incHalozyme therapeutics company profileHalozyme therapeuticsGet free reportModerate buyHalozyme therapeutics daily

Halozyme Therapeutics, Inc (NASDAQ:HALO) Shares Purchased by Gallacher Capital Management LLC

Gallacher Capital Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 85.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,403 shares of the biopharmaceutical company’s stock after acquiring an additional 5,245 shares during the period. […]

United statesMichaelj labarreHalozyme therapeutics company profileAllspring global investments holdingsGoldman sachs groupGallacher capital managementHalozyme therapeutics incHsbc holdingsSecurities exchange commissionHarvey capital management incInternational assets investment managementHalozyme therapeuticsFree reportCapital managementAssets investment managementGlobal investments holdings